SiteOne Therapeutics is a San Francisco-based company that develops novel therapeutics and diagnostics.
SiteOne Therapeutics is a San Francisco-based company that develops novel therapeutics and diagnostics. They develop products safely, effectively, and efficiently treat acute and chronic pain without the limitations of existing therapies, such as NSAIDs and opioids. Their lead therapeutic candidates are highly selective inhibitors of a voltage-gated sodium ion channel, Naᵥ1.7, which plays a critical role in the generation and conduction of pain signals.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Jan 6, 2017 | Series B | $15M | 1 | — | — | Detail |
Jul 15, 2015 | Series Unknown | $1.27M | 1 | — | — | Detail |
Sep 24, 2014 | Series A | $1.50M | 1 | Sears Capital Management | — | Detail |
Investor Name | Lead Investor | Funding Round |
---|---|---|
Sears Capital Management | — | Series B |